1. Pink Sheet
  2. >>Biosimilars & Generics

Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

 
• By Derrick Gingery

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

stopping the Dominio effect
A labeling update approved just before patent expiry may have caused Lyrica generics to be cleared later than expected in the US . • Source: Shutterstock

An well-timed labeling update by Lyrica sponsor Pfizer Inc. appears to have allowed the company to squeeze a few more days of monopoly conditions out of the product in the US before generic competition arrived.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

Biosimilars Industry Celebrates EMA’s Plan to Reduce Clinical Trials

 
• By Dave Wallace

The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.

Trump Tariffs: Indian Pharma Dodges Bullet, But Sword May Remain

 
• By Vibha Ravi

Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.